191 related articles for article (PubMed ID: 34307137)
21. Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors.
Li S; Yuan Y; Xiao H; Dai J; Ye Y; Zhang Q; Zhang Z; Jiang Y; Luo J; Hu J; Chen C; Wang G
Clin Epigenetics; 2019 Mar; 11(1):38. PubMed ID: 30832724
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
Song JS; Kim D; Kwon JH; Kim HR; Choi CM; Jang SJ
Front Oncol; 2019; 9():1055. PubMed ID: 31681591
[No Abstract] [Full Text] [Related]
23. Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors.
Hou X; Lin S; Liu Y; Wang K; Yu Z; Jia J; Yu J; Zheng W; Bai J; Chang L; Chen J; Li M; Chen L
Am J Cancer Res; 2022; 12(5):2387-2396. PubMed ID: 35693087
[TBL] [Abstract][Full Text] [Related]
24. Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors.
Ardeshir-Larijani F; Schneider BP; Althouse SK; Radovich M; Masood A; Perna F; Salman H; Loehrer PJ
JCO Precis Oncol; 2023 Feb; 7():e2200465. PubMed ID: 36787505
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the ITMIG Statement on the WHO Histological Classification and of the Eighth TNM Staging of Thymic Epithelial Tumors of a Series of 188 Thymic Epithelial Tumors.
Meurgey A; Girard N; Merveilleux du Vignaux C; Maury JM; Tronc F; Thivolet-Bejui F; Chalabreysse L
J Thorac Oncol; 2017 Oct; 12(10):1571-1581. PubMed ID: 28694035
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004.
Zhu L; Zhang J; Marx A; Weiss C; Fang WT
J Thorac Dis; 2016 Apr; 8(4):718-26. PubMed ID: 27114840
[TBL] [Abstract][Full Text] [Related]
27. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
28. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.
Petrini I; Meltzer PS; Kim IK; Lucchi M; Park KS; Fontanini G; Gao J; Zucali PA; Calabrese F; Favaretto A; Rea F; Rodriguez-Canales J; Walker RL; Pineda M; Zhu YJ; Lau C; Killian KJ; Bilke S; Voeller D; Dakshanamurthy S; Wang Y; Giaccone G
Nat Genet; 2014 Aug; 46(8):844-9. PubMed ID: 24974848
[TBL] [Abstract][Full Text] [Related]
29. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathological significance of grading on thymic epithelial tumors].
Chen G; Chen W; He W; Jiang Y; Zhou Y; Huang O
Zhonghua Bing Li Xue Za Zhi; 2001 Apr; 30(2):105-9. PubMed ID: 11866964
[TBL] [Abstract][Full Text] [Related]
31. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis.
Janik S; Bekos C; Hacker P; Raunegger T; Ghanim B; Einwallner E; Beer L; Klepetko W; Müllauer L; Ankersmit HJ; Moser B
Oncotarget; 2017 Jul; 8(29):47090-47102. PubMed ID: 28514756
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
Higuchi R; Goto T; Hirotsu Y; Nakagomi T; Yokoyama Y; Otake S; Amemiya K; Oyama T; Omata M
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31683962
[TBL] [Abstract][Full Text] [Related]
33. Can
Nakagawa K; Takahashi S; Endo M; Ohde Y; Kurihara H; Terauchi T
Cancer Manag Res; 2017; 9():761-768. PubMed ID: 29263700
[TBL] [Abstract][Full Text] [Related]
34. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of thymic epithelial tumor subtypes by a quantitative proteomic approach.
Zhao T; Wu J; Liu X; Zhang L; Chen G; Lu H
Analyst; 2018 May; 143(11):2491-2500. PubMed ID: 29645059
[TBL] [Abstract][Full Text] [Related]
36. Is (18)F-FDG PET useful in predicting the WHO grade of malignancy in thymic epithelial tumors? A meta-analysis.
Treglia G; Sadeghi R; Giovanella L; Cafarotti S; Filosso P; Lococo F
Lung Cancer; 2014 Oct; 86(1):5-13. PubMed ID: 25175317
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis in thymic epithelial tumors.
Park SH; Kim HK; Kim H; Ro JY
Pathol Res Pract; 2002; 198(7):461-7. PubMed ID: 12234065
[TBL] [Abstract][Full Text] [Related]
38. Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker.
Li M; Hou F; Zhao J; Zhang T; Li D; Wu W; Liu X; Xu L
Oncol Lett; 2018 Mar; 15(3):3001-3007. PubMed ID: 29435030
[TBL] [Abstract][Full Text] [Related]
39. Rare frequency of gene variation and survival analysis in thymic epithelial tumors.
Song Z; Yu X; Zhang Y
Onco Targets Ther; 2016; 9():6337-6342. PubMed ID: 27789964
[TBL] [Abstract][Full Text] [Related]
40. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
